Skip to content
Recall Observatory FDA recall evidence

Drug product

Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceutical Inc., Berkeley Heights, NJ 07922 NDC 51991-748-10.

D-0216-2026

November 24, 2025

Class II

Product summary

Firm
Breckenridge Pharmaceutical, Inc.
Event
Event 98034
Status
Ongoing
Classification
Class II
Quantity
7389 bottles
Official record key
drug-enforcement:D-0216-2026

Official wording

Reason: CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

Code information: Lot #: 240534C, Exp. Date 01/2027; 240977C, Exp. Date 04/2027.

Distribution pattern: Nationwide within the United States

Derived failure modes

  • Foreign material or chemical contamination

    reason.foreign_material_chemical_contamination · v1.0.0

    N-nitroso-duloxetine impurity
  • Manufacturing or process control

    reason.manufacturing_process_control · v1.0.0

    CGMP Deviations